Nilotinib Stada

Nilotinib, the active ingredient in Nilotinib Stada, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It selectively blocks the BCR‑ABL protein, thereby inhibiting the proliferation of leukemic cells in adults with Philadelphia chromosome‑positive chronic myeloid leukemia.

GNH USA supplies Nilotinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable sourcing and regulatory‑aligned distribution. Our global network ensures timely delivery and adherence to quality standards.

Nilotinib is a tyrosine kinase inhibitor used in the management of chronic myeloid leukemia, targeting the BCR‑ABL signaling pathway. - Chronic phase CML: reduces disease progression and improves long‑term survival. - Accelerated phase CML: achieves hematologic and cytogenetic responses. - Blast phase CML: provides disease control when combined with other therapies.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Rash: skin irritation or erythema. - Fatigue: feeling of tiredness. Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmias. - Severe liver injury: marked elevation of liver enzymes. - Stevens‑Johnson syndrome: severe skin reaction.

Nilotinib therapy requires careful monitoring and patient education. - Cardiac monitoring: obtain baseline ECG and monitor QT interval regularly. - Liver function: assess hepatic enzymes before starting and periodically during therapy. - Blood counts: perform complete blood count monitoring to detect neutropenia or thrombocytopenia. - Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors and QT‑prolonging agents. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with specialist. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Nilotinib can interact with several medication classes, necessitating review before co‑administration. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nilotinib exposure. - QT‑prolonging drugs (e.g., amiodarone, sotalol): raise risk of cardiac arrhythmias. - Antacids containing aluminum or magnesium: reduce nilotinib absorption if taken simultaneously. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower nilotinib levels. - Warfarin: may require INR monitoring due to altered anticoagulant effect. - Statins (e.g., simvastatin, atorvastatin): increased risk of myopathy; dose adjustment may be needed.